• Explore /
  • Poster
  • / Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.

Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.

Abstract Video & Slides Poster

Authors

Christopher Flowers

Christopher Flowers

Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX

Christopher Flowers , Pier Luigi Zinzani , Jiří Mayer , Fontanet Bijou , Ana C. de Oliveira , Yuqin Song , Qingyuan Zhang , Michele Merli , Krimo Bouabdallah , Peter S. Ganly , Huilai Zhang , Sam Yuen , Ed Kingsley , Sarit E. Assouline , Rebecca Auer , Pil Kim , Adam Greenbaum , Sha Huang , Richard Delarue , Judith Trotman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03332017

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7545)

DOI

10.1200/JCO.2023.41.16_suppl.7545

Abstract #

7545

Poster Bd #

96

Abstract Disclosures

Similar Posters

First Author: Pier Luigi Zinzani

First Author: Ian W. Flinn

First Author: Andrew David Zelenetz

First Author: Connie Lee Batlevi